1STBIO and LigaChemBio Announce Strategic R&D and Licensing Option Agreement
Focus on breakthrough ADC payloads and immuno-oncology candidates with out-licensing potential
YONGIN, South Korea, April 22, 2025 — 1ST Biotherapeutics, Inc. ('1STBIO') and LigaChem Biosciences (KOSDAQ: 141080KS, 'LigaChemBio') announced that they have entered into a strategic partnership and licensing option agreement to co-develop novel payloads for antibody-drug conjugates (ADCs) as well as small molecule immuno-oncology therapies.
Under the terms of the agreement, the two companies will collaborate to identify and develop 2–4 novel drug candidates over the next three years, including next-generation ADC payloads and small molecule oncology assets. LigaChemBio will provide initial funding for joint R&D activities and retain exclusive licensing options for the resulting candidates. Upon exercising the option, LigaChemBio will have the right to out-license assets to third parties and share revenues with 1STBIO. Further financial details were not disclosed.
The agreement builds on an ongoing joint research project that began in December 2024. Recognizing a strong fit and potential synergies between the teams, LigaChem Bio opted to expand the alliance. The partnership is expected to overcome limitations of current ADC payloads and unlock first-in-class or best-in-class oncology programs.
'1STBIO's cutting-edge R&D capabilities are at the core of this collaboration,' said Jamie Jae Eun Kim, CEO of 1ST Biotherapeutics. 'By combining our strengths, we aim to not only advance ADC payload innovation, but also to drive meaningful breakthroughs in small molecule immuno-oncology. This expanded partnership reflects our commitment to building sustainable, innovation-driven biotech alliances.'
'We are pleased to collaborate with 1STBIO, a company with strong capabilities in small molecule drug discovery and oncology,' said Yong-Zu Kim, CEO of LigaChemBio. 'Beyond this partnership, we will continue to pursue open innovation with biotech companies worldwide to deliver transformative therapies to patients.'
###
About 1ST Biotherapeutics, Inc.
1ST Biotherapeutics is a science-driven biopharmaceutical company focused on the development of breakthrough therapies in immuno-oncology, neurodegenerative diseases, and rare diseases. Founded in 2016, the Company has developed a pipeline of investigational drugs aimed at addressing critical unmet medical needs. The Company is headquartered in Yongin, South Korea. For more information, visit http://www.1stbio.com
About LigaChem Biosciences
LigaChem Biosciences (LCB, KOSDAQ: 141080) is a clinical-stage biopharmaceutical company focusing on the development of next-generation novel therapeutics utilizing its proprietary medicinal drug discovery technology and ADC platform technology ConjuAll™. Since its foundation in 2006, LCB has focused on the research and development of antibody-drug conjugates (ADCs), anticancer therapeutics based on proprietary platform technologies.
For more information, please visit www.ligachembio.com.
Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts, including statements regarding 1ST Biotherapeutics, Inc. ('1STBIO')'s research and development plans, the potential of its LRRK2-targeting candidates, its participation in the LITE program, and the expected impact of such participation on Parkinson's disease treatment development, are forward-looking statements. These statements reflect 1STBIO's current expectations and projections about future events and are subject to various risks, uncertainties, and assumptions. Actual results may differ materially and adversely from those expressed or implied in these statements due to a variety of factors. 1STBIO undertakes no obligation to update or revise any forward-looking statements to reflect events or circumstances after the date of this press release, except as required by applicable law.
Contact 1ST Biotherapeutics, Inc.
[email protected]
Tel. +82 31 8023 5332
Media InquiriesakampionDr. Ludger Wess / Ines-Regina Buth Managing Partners
[email protected] Tel. +49 40 88 16 59 64 /
Tel. +49 30 23 63 27 68
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
5 hours ago
- Business Wire
Sandisk Forms HBF™ Technical Advisory Board to Guide Development and Strategy for High-Bandwidth Flash Memory Technology
MILPITAS, Calif.--(BUSINESS WIRE)--Sandisk Corporation (NASDAQ: SNDK) today announced the formation of a Technical Advisory Board to guide the development and strategy of its groundbreaking High Bandwidth Flash (HBF™) memory technology. The board includes industry experts and senior technical leaders from both within and outside the company. Appointed today, Professor David Patterson and Raja Koduri will provide strategic guidance, technical insight, market perspective, and shape open standards as Sandisk prepares to launch HBF. 'We're honored to have two distinguished computer architecture experts join our Technical Advisory Board,' said Alper Ilkbahar, Executive Vice President, Chief Technology Officer, and HBF Technical Advisory Board member at Sandisk. 'Their collective experience and strategic counsel will be instrumental in shaping HBF as the future memory standard for the AI industry, and affirming we not only meet but exceed the expectations of our customers and partners.' Professor David Patterson, Pardee Professor of Computer Science, Emeritus at the University of California at Berkeley and a Google distinguished engineer, will lead the Technical Advisory Board and guide the group toward actionable insights and decisions. He is a prominent computer scientist known for co-developing Reduced Instruction Set Computing (RISC), which revolutionized processor design. He played key roles in the development of Redundant Array of Inexpensive Disks (RAID), and Networks of Workstations (NOW). Patterson co-authored the seminal textbook Computer Architecture: A Quantitative Approach and was also awarded the 2017 ACM Turing Award for his contributions to the industry. 'HBF shows the promise of playing an important role in datacenter AI by delivering unprecedented memory capacity at high bandwidth, enabling inference workloads to scale far beyond today's constraints,' said Professor Patterson. 'It could drive down costs of new AI applications that are currently unaffordable.' Raja Koduri is a computer engineer and business executive renowned for leading graphics architecture, with previous positions at AMD as Senior Vice President and Chief Architect and at Intel as Executive Vice President of Accelerated Computing Systems and Graphics. He directed the development of AMD's Polaris, Vega, and Navi GPU architectures, Intel's Arc and Ponte Vecchio GPUs, and spearheaded Intel's foray into discrete graphics. In early 2023, he founded a startup focused on generative AI for gaming, media, and entertainment, and joined the Board of Tenstorrent in the AI and RISC‑V semiconductor space. Most recently, he serves as Founder/CEO of Oxmiq Labs and Co-Founder of Mihira Visual Studios and continues to shape graphics and AI innovation through advisory and board roles across the semiconductor industry. 'HBF is set to revolutionize edge AI by equipping devices with memory capacity and bandwidth capabilities that will support sophisticated models running locally in real time,' said Koduri. 'This advancement will unlock a new era of intelligent edge applications, fundamentally changing how and where AI inference is performed.' Introduced at Future FWD: Sandisk 2025 Investor Day, HBF is a breakthrough memory solution designed to augment High Bandwidth Memory (HBM) for AI inference workloads, offering comparable bandwidth while delivering up to 8x the capacity at a similar cost. Enabled by BiCS technology and CBA wafer bonding, HBF leverages proprietary stacking with ultra-low die warpage for 16-high configurations. Its architecture has been developed over the past year with input from leading AI industry players. For more information about HBF, please visit this Fact Sheet. About Sandisk Sandisk (Nasdaq: SNDK) delivers innovative Flash solutions and advanced memory technologies that meet people and businesses at the intersection of their aspirations and the moment, enabling them to keep moving and pushing possibility forward. Follow Sandisk on Instagram, Facebook, X, LinkedIn, and YouTube. Join TeamSandisk on Instagram. Sandisk and the Sandisk logo are registered trademarks or trademarks of Sandisk Corporation or its affiliates in the U.S. and/or other countries. All other marks are the property of their respective owners. Product specifications subject to change without notice. © 2025 Sandisk Corporation or its affiliates. All rights reserved.
Hamilton Spectator
9 hours ago
- Hamilton Spectator
VERSES® Featured in IEEE Spectrum
VANCOUVER, British Columbia, July 25, 2025 (GLOBE NEWSWIRE) — VERSES AI Inc. (CBOE: VERS) (OTCQB: VRSSF) ('VERSES'' or the 'Company'), a cognitive computing company specializing in next-generation agentic software systems, has been featured in IEEE Spectrum, the flagship publication of the IEEE, the world's largest professional organization devoted to engineering and the applied sciences. The article, co-authored by VERSES CEO Gabriel René, addresses questions such as: Why does the Spatial Web matter? How, exactly, can it make the world better? These are answered with five example use cases for the Spatial Web: VERSES CEO Gabriel René said 'I am delighted to see our vision of the Spatial Web in IEEE Spectrum. These standards will make it easier for our product, Genius™, to interconnect a physical world-full of devices, phones, wearables, robots, drones, and even AI agents. For Genius customers, this can mean quicker development and deployment and lower integration costs.' The article can be found at: About VERSES VERSES® is a cognitive computing company building next-generation intelligent software systems modeled after the wisdom and genius of Nature. Designed around first principles found in science, physics and biology, our flagship product, Genius,™ is an agentic enterprise intelligence platform designed to generate reliable domain-specific predictions and decisions under uncertainty. Imagine a Smarter World that elevates human potential through technology inspired by Nature. Learn more at , LinkedIn and X . On behalf of the Company Gabriel René, Founder & CEO, VERSES AI Inc. Press Inquiries: press@ Investor Relations Inquiries James Christodoulou, Chief Financial Officer IR@ , +1(212)970-8889
Business Wire
9 hours ago
- Business Wire
Bradford Health Services Earns Coveted "Great Place To Work"® Certification
BIRMINGHAM, Ala.--(BUSINESS WIRE)-- Bradford Health Services, a leading provider of drug and alcohol addiction treatment across the Southeastern U.S., today announced it has been officially certified as a Great Place To Work®. This recognition, awarded by the global authority on workplace culture, underscores Bradford Health's commitment to building a supportive, inclusive, and high-trust environment for its more than 1,600 U.S.-based employees. 'This certification is a reflection of the servant-leadership philosophy that guides us at Bradford,' said Rob Marsh, Chief Executive Officer. Share Bradford Health achieved certification with 67% of employees reporting a positive experience at work, surpassing the typical U.S.-based company average of 57%. Key areas of strength highlighted by employees include: 89% agree they are entrusted with significant responsibilities. 86% say their work has special meaning beyond being 'just a job,' and that they felt welcomed upon joining. 84% affirm they feel they make a difference in the organization. 82% report they can be themselves at work. 'This certification is a reflection of the servant-leadership philosophy that guides us at Bradford,' said Rob Marsh, Chief Executive Officer. 'We've built a culture where our people come first—where leaders exist to support, uplift, and empower our teams to live out our mission with purpose and compassion.' Great Place To Work® conducts its evaluations using its proprietary Trust Index™ survey and Trust Model™, which assess culture across five pillars: credibility, respect, fairness, pride, and camaraderie. About Bradford Health Services With 40 years of experience, Bradford Health Services operates addiction treatment centers in Alabama, Florida, Mississippi, North Carolina, Tennessee, and Texas. The organization is accredited by The Joint Commission and delivers evidence-based care at every stage of the recovery journey. About Great Place To Work® Certification Great Place To Work® Certification ™ is the gold standard for workplace culture recognition. Based on anonymous employee feedback, the certification recognizes organizations that foster high levels of trust, pride, and camaraderie.
